TX-FLUENCE
29.2.2024 14:31:32 CET | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced its newest LED top light solutions for produce and ornamental cultivators: RAPTR 2 and VYPR 4.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240229846318/en/
Fluence announced its newest LED top light solutions for produce and ornamental cultivators: RAPTR 2 and VYPR 4. (Photo: Business Wire)
Fluence’s latest LED innovations were developed in parallel with the company’s global research program, which includes partnerships with industry leaders worldwide and in-house analysis of spectral optimization across crops. The new RAPTR and VYPR offerings build upon Fluence’s existing portfolio of lighting solutions to offer robust fixtures with higher wattages, greater efficiencies and overall increased ROI for growers throughout the world.
RAPTR 2: Higher wattages and tunable spectra help growers maximize light output and efficiency at lower installation costs
The RAPTR 2 fixture’s wide power range (up to 1400 W), multi-channel tunable spectra and up to 5050 μmol/s of light output make it the optimal lighting solution for upgrading HPS fixtures in greenhouse environments. Featuring steerable spectra—including far red—integrated wireless dimming capability and efficacies up to 4.0 μmol/J, cultivators can achieve improved crop performance and lower operating expenses with the new RAPTR 2.
“The latest RAPTR and VYPR series luminaires showcase that Fluence’s primary mission remains unchanged: Help the world grow smarter through the most advanced LED fixtures,” said Steve Graves, senior vice president of strategy and business development at Fluence. “We're excited to launch our most powerful and efficient solutions yet and we look forward to advancing the industry together with partners across the globe.”
VYPR 4: More versatility and control that maximizes cultivation results
Featuring the VYPR line’s familiar low-profile design, VYPR 4 offers more spectral options, light uniformity at any mounting height, easy installation and higher light intensities with lower energy consumption.
“VYPR 4 is a versatile top light solution,” said Jordon Musser, chief product officer for Fluence. “The latest generation focuses on what every grower wants: a more efficient output that yields a clear ROI. Installation is swift, the fixtures are extremely durable, and growers can tap into Fluence’s diverse spectral options to curate a lighting program unique to their cultivation goals.”
VYPR 4 features output up to 3030 μmol/s and efficiency up to 3.9 μmol/J. The fixture also includes dual-channel far red spectra as well as Fluence’s wide variety of PhysioSpec™ spectra to empower growers with multiple lighting strategies. VYPR 4’s low profile creates the least possible shading in a greenhouse environment and now offers a wide-beam optic for optimized light distribution.
Fluence will showcase RAPTR 2 and VYPR 4 during its upcoming global trade shows, including HortiContact from March 5 to March 7, 2024 in the Netherlands.
To learn more about the RAPTR and VYPR series and how to schedule a trial at your facility, visit www.fluence-led.com.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis, produce and flower markets, committed to enabling more efficient crop production for the world’s top greenhouse and indoor growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Professional Business. For more information about Fluence, visit www.fluence-led.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240229846318/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom